AA
EWTX icon

AlphaCentric Advisors’s Edgewise Therapeutics EWTX Stock Holding History

AlphaCentric Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$644K Buy
15,840
+225
+1% +$7.76K 0.55% 62
2026
Q1 		$492K Buy
15,615
+912
+6% +$26.3K 0.49% 63
2025
Q4 		$365K Buy
+14,703
New +$295K 0.36% 89
2024
Q4 		$275K Buy
+10,316
New +$328K 0.27% 91

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AlphaCentric Advisors's EWTX Position: Q2 2026 in Review

AlphaCentric Advisors increased its Edgewise Therapeutics (EWTX) stake by 1.4% in Q2 2026, buying an estimated $7.76K and bringing the position to 15,840 shares worth $644K. The position accounts for 0.55% of the portfolio, ranked #62.

AlphaCentric Advisors first reported a position in EWTX in Q4 2024 and has held it in 4 quarters since. 227 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • AlphaCentric Advisors held 15,840 shares of Edgewise Therapeutics worth $644K as of Q2 2026.
  • AlphaCentric Advisors bought 225 Edgewise Therapeutics shares in Q2 2026, an estimated $7.76K.
  • Edgewise Therapeutics made up 0.55% of AlphaCentric Advisors's portfolio in Q2 2026, its #62 holding.
  • AlphaCentric Advisors first reported a position in Edgewise Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 227 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.